CADILAHC Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > cadilahc

Technical Analysis

Technical Strength: 5 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 49.3. According to RSI analysis, cadilahc is marginally weak. 4.0 CADILAHC RSI Chart
MACD (?) MACD: 1.49 and Signal Line: 0.533. According to MACD analysis, cadilahc is technically strong. 8.0 CADILAHC MACD Chart
Simple Moving Average (?) According to simple moving average analysis, cadilahc is in a uptrend. Support level is at 489. 9.0 CADILAHC Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, cadilahc is facing resistance at 492 and support level is at 467.8669. 3.0 CADILAHC Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.532. 5.0 CADILAHC Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above 38.2% level. Support is at 482.8118. Resistance levels are 497.55 and 512.2882. 3.0 CADILAHC Fibonacci Retracement Chart
Average True Range (?) ATR: 13.8 NA CADILAHC Average True Range Chart
Average Directional Index (?) ADX is 12 which means CADILAHC is in a trading range and there is no trend. NA CADILAHC Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
October 19, 2017
Open Price 493.0
High Price 496.5
Low Price 487.75
Close Price 490.75
Absolute Change -0.7
Percentage Change -0.142%
Weekly Change -1.96%
Monthly Change 0.801%
Yearly Change 25.8%
52-week high 560.0
52-week low 328.8
Corporate Actions
ExDate Purpose
July 27, 2017 ANNUAL GENERAL MEETING
March 16, 2017 INT DIV RS 3.20 PER SHARE
March 16, 2017 INTERIM DIVIDEND
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.383
Confidence in Beta1.24%
Market Capital Rs. 10048.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 17.636
TTM Price-to-Earnings (P/E) Ratio 27.8
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 19 October 2017: Deliverable Quantity:2.17e+04 NA CADILAHC Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 19 October 2017: Daily Volatility:0.3554 NA CADILAHC Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 19 October 2017: PCR_OI:0 PCR:0 NA CADILAHC PCR Chart
Option Pain (?) 19 October 2017: Max Pain:500.0 NA CADILAHC Option Pain Chart
Premium (?) 19 October 2017 Premium: 0.85 Futures OI:3057600.0 NA CADILAHC Premium Chart
Option_MAX_OI (?) 19 October 2017: Price:490.75 Put with maximum OI:0.0 Call with maximum OI:520.0 NA CADILAHC Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
October 26, 2017 491.6 3057600.0 165.0 171.0 490.75
November 30, 2017 492.8 105600.0 8.0 8.0 490.75

Announcements

October 16, 2017 CaPress Releaseadila Healthcare Limited has informed the Exchange regarding a press release dated October 14, 2017, titled "Zydus receives final approval from the USFDA for Allopurinol Tablets USP".
October 09, 2017 CaPress Releaseadila Healthcare Limited has informed the Exchange regarding a press release dated October 07, 2017, titled "Zydus receives final approval from the USFDA for Amitriptyline Hydrochloride Tablets USP.".
See all Announcements

Board Meetings

Date Meeting Date Purpose
October 11, 2017 November 14, 2017 TResultsTo consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2017.
July 17, 2017 August 11, 2017 toResultso consider, inter alia, approve the unaudited financial results for the quarter ended on June 30, 2017.
See all Board Meetings

CADILAHC is part of...

Index Weightage
CNXPHARMA NA

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 478.1 Rs. 482.9 Rs. 486.8 Rs. 491.7 Rs. 495.6 Rs. 500.4 Rs. 504.3